Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer


Phase II Study of Carboxyamidotriazole (CAI, NSC #609974) in Patients With Advanced Renal Cell Carcinoma Refractory to Immunotherapy


Carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor.


Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients who have advanced kidney cancer that has not responded to biological therapy.

Study Status: Completed


Condition Intervention Phase
Kidney Cancer Drug: carboxyamidotriazole Phase 2

Verified by Eastern Cooperative Oncology Group December, 2005

Sponsored by: Eastern Cooperative Oncology Group
Information provided by: National Cancer Institute (NCI) identifier: NCT00005045

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

David Friedland, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site